Feb 27 (Reuters) – The U.S. Food and Drug Administration on Friday approved Ascendis Pharma’s once-weekly therapy for children with a rare genetic disorder that causes dwarfism, the company said.
(Reporting by Sahil Pandey and Puyaan Singh in Bengaluru; Editing by Tasim Zahid)
Brought to you by www.srnnews.com